JP7677646B2 - 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤 - Google Patents

複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤 Download PDF

Info

Publication number
JP7677646B2
JP7677646B2 JP2022535116A JP2022535116A JP7677646B2 JP 7677646 B2 JP7677646 B2 JP 7677646B2 JP 2022535116 A JP2022535116 A JP 2022535116A JP 2022535116 A JP2022535116 A JP 2022535116A JP 7677646 B2 JP7677646 B2 JP 7677646B2
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
ceutically acceptable
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505690A (ja
JP2023505690A5 (https=
Inventor
ターチ，ジョン・ジェイ
ガバンデ，ナブナス
Original Assignee
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー filed Critical ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー
Publication of JP2023505690A publication Critical patent/JP2023505690A/ja
Publication of JP2023505690A5 publication Critical patent/JP2023505690A5/ja
Application granted granted Critical
Publication of JP7677646B2 publication Critical patent/JP7677646B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022535116A 2019-12-10 2020-12-10 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤 Active JP7677646B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946100P 2019-12-10 2019-12-10
US62/946,100 2019-12-10
PCT/US2020/064191 WO2021119242A1 (en) 2019-12-10 2020-12-10 Replication protein a (rpa)-dna interaction inhibitors

Publications (3)

Publication Number Publication Date
JP2023505690A JP2023505690A (ja) 2023-02-10
JP2023505690A5 JP2023505690A5 (https=) 2023-12-14
JP7677646B2 true JP7677646B2 (ja) 2025-05-15

Family

ID=76330773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535116A Active JP7677646B2 (ja) 2019-12-10 2020-12-10 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤

Country Status (6)

Country Link
US (1) US12486246B2 (https=)
EP (1) EP4073055A4 (https=)
JP (1) JP7677646B2 (https=)
BR (1) BR112022011372A2 (https=)
CA (1) CA3162280A1 (https=)
WO (1) WO2021119242A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523670A (ja) 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2013518906A (ja) 2010-02-05 2013-05-23 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 複製タンパク質ａを阻害する物質および方法ならびにその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
US20100055116A1 (en) 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
WO2008045663A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008148747A2 (en) 2007-06-08 2008-12-11 University Of Copenhagen Pdz domain modulators
US8476458B2 (en) 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
HRP20161004T1 (hr) 2007-09-27 2016-10-21 Dow Agrosciences Llc Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata
WO2009145829A1 (en) 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
WO2012037573A1 (en) 2010-09-17 2012-03-22 Indiana University Research And Technology Corporation Small molecule inhibitors of replication protein a that also act synergistically with cisplatin
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
JP6482546B2 (ja) 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 二重対立遺伝子ノックアウトを生成するための方法および組成物
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
ITMI20131410A1 (it) 2013-08-26 2015-02-27 Univ Degli Studi Modena E Reggio Emilia Composti e composizioni per l'uso nella inibizione dell' interazione lbc-rhoa
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2016077752A2 (en) * 2014-11-13 2016-05-19 Indiana University Research And Technology Corporation Materials and method for inhibiting replication protein a and uses thereof
WO2017205503A1 (en) 2016-05-24 2017-11-30 Indiana University Research And Technology Corporation Ku inhibitors and their use
CA3075734A1 (en) 2017-09-19 2019-03-28 Indiana University Research And Technology Corporation Xpa inhibitor compounds and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523670A (ja) 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2013518906A (ja) 2010-02-05 2013-05-23 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 複製タンパク質ａを阻害する物質および方法ならびにその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology，2015年，93(1)，P.25-33

Also Published As

Publication number Publication date
US12486246B2 (en) 2025-12-02
CA3162280A1 (en) 2021-06-17
EP4073055A1 (en) 2022-10-19
BR112022011372A2 (pt) 2022-08-23
US20230056729A1 (en) 2023-02-23
WO2021119242A1 (en) 2021-06-17
JP2023505690A (ja) 2023-02-10
EP4073055A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP5808408B2 (ja) フタラジノンケトン誘導体、その製造法および医薬用途
EP2253625B1 (en) Pyridazinones, the preparation and the use thereof
JP6078640B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
EP2799437B1 (en) Quinoline and cinnoline derivatives and use thereof
DK2998296T3 (en) CYCLOYLIC ACID DERIVATIVE, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF
KR20150014452A (ko) Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 화합물 및 조성물
ES2927959T3 (es) Compuestos de imidazol heterocíclicos, composiciones farmacéuticas de los mismos, método de preparación de los mismos y uso de los mismos
AU2016320073A1 (en) Compound for treating or preventing hyperuricemia or gout
EP2646427A1 (en) Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
JP6908805B2 (ja) Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
JP7677646B2 (ja) 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤
CN109476649B (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
TWI864050B (zh) 環狀去氧核糖核苷酸化合物
CN117083265A (zh) 激酶抑制剂及其用途
KR20150134731A (ko) 오로라 키나아제 억제 활성을 갖는 신규한 트리아졸일살리실아마이드 유도체
WO2017181974A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
JP6510498B2 (ja) 腫瘍疾患の治療に有用な化合物
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
WO2017181973A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
KR20240111305A (ko) 페롭토시스 유도 활성을 갖는 화합물
WO2023070076A1 (en) Compounds for cancers driven by braf mutation
KR20260029377A (ko) 암 및 염증성 질환 치료에 사용하기 위한 이미다조[1,2-α]피리딘 화합물 및 그 화합물의 제조 방법
TW202602447A (zh) 用於傷口治療之wnt途徑抑制劑之醫藥組合物
WO2025240834A1 (en) Nsd2-targeted chemical degraders and compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250423

R150 Certificate of patent or registration of utility model

Ref document number: 7677646

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150